What it is

Hi1a is a venom-derived peptide isolated from the Australian funnel-web spider Hadronyche infensa. It is notable for its size (reported as 76 amino acids) and for an intricate disulfide-rich fold sometimes described as a “double-knot” structure.

Hi1a is being investigated as a potential neuroprotective agent in ischemic stroke. The translational story depends not only on biological activity, but also on whether the peptide can be produced reliably at high purity and correctly folded.

Why people care about it

The interest in Hi1a is driven by the broader search for treatments that can reduce tissue damage after ischemic stroke. Venom peptides are a recurring source of potent and selective bioactive molecules, but they can be difficult to manufacture and to turn into scalable medicines.

What we know vs what we do not know

What we know:

Hi1a is a real peptide with a defined origin and active research program.
Production (recombinant expression and traditional synthesis) has been a bottleneck in parts of the literature.

What we do not know:

Whether Hi1a will translate into safe, effective clinical benefit for stroke.
The optimal formulation, dosing, delivery, and safety profile in humans.

Latest updates

2026-03-20 (J Org Chem): A paper reported the first “single-shot” chemical synthesis of Hi1a using automated fast-flow peptide synthesis (AFPS), producing >10 mg of linear Hi1a in under 4.5 hours of total synthesis time. This is a manufacturing workflow result, not a clinical efficacy update.
- https://pubmed.ncbi.nlm.nih.gov/41081677/ (doi:10.1021/acs.joc.5c01533)

Safety reality

Hi1a is not an approved drug. Any non-regulated product claiming to be Hi1a has substantial risks around identity, purity, folding state, and contaminants.

References

Byrne SA, et al. Rapid Chemical Synthesis of Neuroprotective Hi1a. J Org Chem. (2026). https://pubmed.ncbi.nlm.nih.gov/41081677/ doi:10.1021/acs.joc.5c01533